Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: TRASTUZUMAB, . Treffer: 17
2022
Bartsch, R; Gampenrieder, SP; Rinnerthaler, G; Petru, E; Egle, D; Petzer, A; Balic, M; Pluschnig, U; Sliwa, T; Singer, C
Updated Austrian treatment algorithm in HER2+metastatic breast cancer
WIEN KLIN WOCHENSCHR. 2022; 134(1-2): 63-72.
Doi: 10.1007/s00508-021-01987-9
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Klymiuk, I; Bilgilier, C; Mahnert, A; Prokesch, A; Heininger, C; Brandl, I; Sahbegovic, H; Singer, C; Fuereder, T; Steininger, C
Chemotherapy-associated oral microbiome changes in breast cancer patients.
Front Oncol. 2022; 12:949071
Doi: 10.3389/fonc.2022.949071
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Posch, F; Niedrist, T; Glantschnig, T; Firla, S; Moik, F; Kolesnik, E; Wallner, M; Verheyen, N; Jost, PJ; Zirlik, A; Pichler, M; Balic, M; Rainer, PP
Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer.
Front Cardiovasc Med. 2022; 9: 933428
Doi: 10.3389/fcvm.2022.933428
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Suppan, C
ESMO 2021-my top three abstracts in breast cancer
MEMO-MAG EUR MED ONC. 2022;
Doi: 10.1007/s12254-022-00810-z
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2021
Balic, M; Rinnerthaler, G; Bartsch, R
Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast Cancer
BREAST CARE. 2021;
Doi: 10.1159/000518696
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Suppan, C; Steiner, D; Klocker, EV; Posch, F; Henzinger, E; Muller, HD; Stoger, H; Dandachi, N; Balic, M
Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
BREAST CARE. 2021;
Doi: 10.1159/000513766
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2020
Huemer, F; Weiss, L; Regitnig, P; Winder, T; Hartmann, B; Thaler, J; Piringer, G; Schmitt, CA; Eisterer, W; Gänzer, H; Wüstner, A; Andel, J; Jagdt, B; Ulmer, H; Greil, R; Wöll, E
Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry.
J Clin Med. 2020; 9(4):
Doi: 10.3390/jcm9040935
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2019
Suppan, C; Balic, M
Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer The best of ASCO 2019
MEMO-MAG EUR MED ONC. 2019;
Doi: 10.1007/s12254-019-00530-x
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
2017
Singer, CF; Tan, YY; Fitzal, F; Steger, GG; Egle, D; Reiner, A; Rudas, M; Moinfar, F; Gruber, C; Petru, E; Bartsch, R; Tendl, KA; Fuchs, D; Seifert, M; Exner, R; Balic, M; Bago-Horvath, Z; Filipits, M; Gnant, M; Austrian Breast and Colorectal Cancer Study Group
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
Clin Cancer Res. 2017; 23(14):3676-3683
Doi: 10.1158/1078-0432.CCR-16-2373
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2016
Czink, E; Heining, C; Weber, TF; Lasitschka, F; Schemmer, P; Schirmacher, P; Weiss, KH; Glimm, H; Brors, B; Weichert, W; Jäger, D; Fröhling, S; Springfeld, C
[Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer].
Z Gastroenterol. 2016; 54(5):426-430
Doi: 10.1055/s-0042-103498
Web of Science
PubMed
FullText
FullText_MUG
Grillo, F; Fassan, M; Sarocchi, F; Fiocca, R; Mastracci, L
HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice.
World J Gastroenterol. 2016; 22(26): 5879-5887.
Doi: 10.3748/wjg.v22.i26.5879
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Schramm, A; Friedl, TW; Schochter, F; Scholz, C; de Gregorio, N; Huober, J; Rack, B; Trapp, E; Alunni-Fabbroni, M; Müller, V; Schneeweiss, A; Pantel, K; Meier-Stiegen, F; Hartkopf, A; Taran, FA; Wallwiener, D; Janni, W; Fehm, T
Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Arch Gynecol Obstet. 2016; 293(2):271-281
Doi: 10.1007/s00404-015-3879-7
Web of Science
PubMed
FullText
FullText_MUG
2015
Pircher, M; Mlineritsch, B; Fridrik, MA; Dittrich, C; Lang, A; Petru, E; Weltermann, A; Thaler, J; Hufnagl, C; Gampenrieder, SP; Rinnerthaler, G; Ressler, S; Ulmer, H; Greil, R
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Anticancer Res. 2015; 35(1):517-521
Web of Science
PubMed
2014
Steger, GG; Greil, R; Lang, A; Rudas, M; Fitzal, F; Mlineritsch, B; Hartmann, BL; Bartsch, R; Melbinger, E; Hubalek, M; Stoeger, H; Dubsky, P; Ressler, S; Petzer, AL; Singer, CF; Muss, C; Jakesz, R; Gampenrieder, SP; Zielinski, CC; Fesl, C; Gnant, M
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)
ANN ONCOL. 2014; 25(2): 366-371.
Doi: 10.1093/annonc/mdt508
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2009
Reim, F; Dombrowski, Y; Ritter, C; Buttmann, M; Hausler, S; Ossadnik, M; Krockenberger, M; Beier, D; Beier, CP; Dietl, J; Becker, JC; Honig, A; Wischhusen, J
Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Cancer Res. 2009; 69(20):8058-8066
Doi: 10.1158/0008-5472.CAN-09-0834
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2006
Bjelic-Radisic, V; Stöger, H; Winter, R; Beham-Schmid, C; Petru, E
Long-term control of bone marrow carcinosis and severe thrombocytopenia with standard-dose chemotherapy in a breast cancer patient: a case report.
Anticancer Res. 2006; 26(2B):1627-1630
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
Google Scholar
2005
Reich, O; Liegl, B; Tamussino, K; Regauer, S
p185HER2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget's disease.
Mod Pathol. 2005; 18(3):354-357
Doi: 10.1038/modpathol.3800243
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG